TaiMed Biologics press release
TaiMed Biologics, a commercial-stage CD4-targeted biologics company advancing antibody-based therapies for long-acting HIV treatment, announced results from two studies to be presented at IDWeek 2026, October 21-24 in Washington, D.C. The findings highlight TMB-365’s own clinical activity and potential as a component of multiple long-acting HIV combinations, alongside laboratory evidence of complementary antiviral susceptibility supporting the company’s TMB-365/TMB-380 maintenance regimen.
Read the full press release here.
Source : TaiMed Biologics
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.